Compare Payoneer Global Inc (PAYO) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Payoneer Global Inc vs BIO-TECHNE Corp — how do they compare? Payoneer Global Inc trades at $7.15 (market cap $2.43B), while BIO-TECHNE Corp trades at $72.44 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 4.7× Payoneer Global Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Payoneer Global Inc for 61 Days and BIO-TECHNE Corp for 64 Days on average.
| PAYO | TECH | |
|---|---|---|
Market Cap | $2.43B | $11.36B |
Volume | 1,342,701 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $7.18 | $72.61 |
52-Week Low | $4.27 | $43.31 |
Typical Hold Time | 61 Days | 64 Days |
Enterprise Value | $2.17B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Payoneer Global (PAYO) trades at $7.14, down 0.28% on the day, with a bullish technical outlook supported by moving averages. The company reported Q2 2026 earnings of $0.02 per share, missing estimates, but maintains strong revenue growth and a 78% gross margin. Recent news highlights the renewal of its partnership with Etsy through 2029 and ongoing acquisition discussions with Nuvei.
The stock presents a mixed outlook: analyst consensus is 60% buy with no sell ratings, but elevated P/E of 51.18 and recent earnings misses pose valuation and execution risks. The pending acquisition adds uncertainty, while expansion into India offers growth potential. Investors should weigh strong fundamentals against high expectations and integration challenges.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
